Resveratrol inhibits cancer cell metabolism by down regulating pyruvate kinase M2 via inhibition of Mammalian target of Rapamycin

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Iqbal, Mohd Askandar ^a   Bamezai, Rameshwar N K ^a,b  

^a JAWAHARLAL NEHRU UNIVERSITY   (India)

^b SHRI MATA VAISHNO DEVI UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

LACTIC ACID; MAMMALIAN TARGET OF RAPAMYCIN; PYRUVATE KINASE; PYRUVATE KINASE M2; RESVERATROL; RIBOSE 5 PHOSPHATE; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; GLUCOSE; MESSENGER RNA; STILBENE DERIVATIVE; TARGET OF RAPAMYCIN KINASE;

ARTICLE; BIOSYNTHESIS; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL METABOLISM; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME INHIBITION; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; HUMAN CELL; MACROMOLECULE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; AEROBIC METABOLISM; DRUG ANTAGONISM; DRUG EFFECT; GENE SILENCING; GENETICS; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

MAMMALIA;

AEROBIOSIS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; GENE SILENCING; GLUCOSE; GLYCOLYSIS; HUMANS; LACTIC ACID; PYRUVATE KINASE; RNA, MESSENGER; STILBENES; TOR SERINE-THREONINE KINASES;

EID: 84860499082     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036764     Document Type: Article

References (36)

1. Mazurek S, Boschek CB, Hugo F, Eigenbrodt E, (2005) Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol 15: 300-308.
2. Vander Heiden MG, Cantley LC, Thompson CB, (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324: 1029-1033.
3. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, et al. (2004) mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10: 594-601.
4. Ligresti G, Militello L, Steelman LS, Cavallaro A, Basile F, et al. (2009) PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. Cell Cycle 8: 1352-1358.
5. Samuels Y, Waldman T Oncogenic mutations of PIK3CA in human cancers. Curr Top Microbiol Immunol 347: 21-41.
6. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, et al. (2008) The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452: 230-233.
7. Yamada K, Noguchi T, (1999) Nutrient and hormonal regulation of pyruvate kinase gene expression. Biochem J 337 (Pt 1): 1-11.
8. Yamada K, Noguchi T, (1999) Regulation of pyruvate kinase M gene expression. Biochem Biophys Res Commun 256: 257-262.
9. Mazurek S, Grimm H, Boschek CB, Vaupel P, Eigenbrodt E, (2002) Pyruvate kinase type M2: a crossroad in the tumor metabolome. Br J Nutr 87 (Suppl 1): S23-29.
10. Kayne FJ, Price NC, (1973) Amino acid effector binding to rabbit muscle pyruvate kinase. Arch Biochem Biophys 159: 292-296.
11. Valentini G, Chiarelli L, Fortin R, Speranza ML, Galizzi A, et al. (2000) The allosteric regulation of pyruvate kinase. J Biol Chem 275: 18145-18152.
12. Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB, (2008) Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev 18: 54-61.
13. Ewald N, Toepler M, Akinci A, Kloer HU, Bretzel RG, et al. (2005) [Pyruvate kinase M2 (tumor M2-PK) as a screening tool for colorectal cancer (CRC). A review of current published data]. Z Gastroenterol 43: 1313-1317.
14. Hardt PD, Ewald N, (2008) Tumor M2 pyruvate kinase: a tumor marker and its clinical application in gastrointestinal malignancy. Expert Rev Mol Diagn 8: 579-585.
15. Hardt PD, Mazurek S, Toepler M, Schlierbach P, Bretzel RG, et al. (2004) Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer. Br J Cancer 91: 980-984.
16. Gupta V, Kalaiarasan P, Faheem M, Singh N, Iqbal MA, et al. Dominant negative mutations affect oligomerization of human pyruvate kinase M2 isozyme and promote cellular growth and polyploidy. J Biol Chem 285: 16864-16873.
17. Tennant DA, Duran RV, Gottlieb E Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 10: 267-277.
18. Baur JA, Sinclair DA, (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5: 493-506.
19. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, et al. (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218-220.
20. Sgambato A, Ardito R, Faraglia B, Boninsegna A, Wolf FI, et al. (2001) Resveratrol, a natural phenolic compound, inhibits cell proliferation and prevents oxidative DNA damage. Mutat Res 496: 171-180.
21. Li Y, Liu J, Liu X, Xing K, Wang Y, et al. (2006) Resveratrol-induced cell inhibition of growth and apoptosis in MCF7 human breast cancer cells are associated with modulation of phosphorylated Akt and caspase-9. Appl Biochem Biotechnol 135: 181-192.
22. Whyte L, Huang YY, Torres K, Mehta RG, (2007) Molecular mechanisms of resveratrol action in lung cancer cells using dual protein and microarray analyses. Cancer Res 67: 12007-12017.
23. Fustier P, Le Corre L, Chalabi N, Vissac-Sabatier C, Communal Y, et al. (2003) Resveratrol increases BRCA1 and BRCA2 mRNA expression in breast tumour cell lines. Br J Cancer 89: 168-172.
24. Kim YA, Lee WH, Choi TH, Rhee SH, Park KY, et al. (2003) Involvement of p21WAF1/CIP1, pRB, Bax and NF-kappaB in induction of growth arrest and apoptosis by resveratrol in human lung carcinoma A549 cells. Int J Oncol 23: 1143-1149.
25. Lin JN, Lin VC, Rau KM, Shieh PC, Kuo DH, et al. Resveratrol modulates tumor cell proliferation and protein translation via SIRT1-dependent AMPK activation. J Agric Food Chem 58: 1584-1592.
26. Faber AC, Dufort FJ, Blair D, Wagner D, Roberts MF, et al. (2006) Inhibition of phosphatidylinositol 3-kinase-mediated glucose metabolism coincides with resveratrol-induced cell cycle arrest in human diffuse large B-cell lymphomas. Biochem Pharmacol 72: 1246-1256.
27. Liu M, Wilk SA, Wang A, Zhou L, Wang RH, et al. Resveratrol inhibits mTOR signaling by promoting the interaction between mTOR and DEPTOR. J Biol Chem 285: 36387-36394.
28. Sabatine MS, Liu E, Morrow DA, Heller E, McCarroll R, et al. (2005) Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation 112: 3868-3875.
29. Netzker R, Greiner E, Eigenbrodt E, Noguchi T, Tanaka T, et al. (1992) Cell cycle-associated expression of M2-type isozyme of pyruvate kinase in proliferating rat thymocytes. J Biol Chem 267: 6421-6424.
30. Knobbe CB, Lapin V, Suzuki A, Mak TW, (2008) The roles of PTEN in development, physiology and tumorigenesis in mouse models: a tissue-by-tissue survey. Oncogene 27: 5398-5415.
31. Efeyan A, Sabatini DM mTOR and cancer: many loops in one pathway. Curr Opin Cell Biol 22: 169-176.
32. Salmena L, Carracedo A, Pandolfi PP, (2008) Tenets of PTEN tumor suppression. Cell 133: 403-414.
33. Hill R, Calvopina JH, Kim C, Wang Y, Dawson DW, et al. PTEN loss accelerates KrasG12D-induced pancreatic cancer development. Cancer Res 70: 7114-7124.
34. Sun Q, Chen X, Ma J, Peng H, Wang F, et al. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci U S A 108: 4129-4134.
35. Kueck A, Opipari AW Jr, Griffith KA, Tan L, Choi M, et al. (2007) Resveratrol inhibits glucose metabolism in human ovarian cancer cells. Gynecol Oncol 107: 450-457.
36. Gatenby RA, Gillies RJ, (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4: 891-899.